Pharmaceutical - North America


Current filters:

North America

Popular Filters

7066 to 7090 of 7233 results

Pfizer and Bristol-Myers get first approval for blood thinner Eliquis, in EU


Following a positive recommendation from its drug advisory body (The Pharma Letter March 21), the European…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

German biopharmaceuticals’ growth curbed by drug pricing reforms


Demand for biopharmaceuticals continued to expand in Germany last year. Turnover in the genetically engineered…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalPricingResearch

Canadian cancer research group spins out three companies


Canada’s Ontario Institute for Cancer Research (OICR) has announced investments in three new Ontario…

FinancialNorth AmericaOncologyResearch

GAVI commits $100 million to fight meningitis A


The GAVI Alliance has committed $100 million to help tackle meningitis A in Cameroon, Chad and Nigeria,…

FinancialMenAfriVacPharmaceuticalRest of the WorldVaccines

Fight over user fees underscores bigger questions about US FDA's mission, Burrill report finds


Industry frustration is growing over a failure to adequately fund the US Food and Drug Administration…

FinancialNorth AmericaPharmaceuticalRegulation

GlaxoSmithKline’s diabetes drug Avandia to be restricted on US market


As part of a US Food and Drug Administration re-assessment of UK drug giant GlaxoSmithKline’s troubled…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Sandoz files for generic of Shire’s Vyvanse; FDA warning


Ireland-headquartered biopharmaceutical company Shire (LSE: SHP) yesterday revealed that its US subsidiary…

GenericsMarkets & MarketingNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozShireVyvanse

Pfizer Ph II study confirms efficacy of Ablynx' ozoralizumab in RA


Belgian drug developer Ablynx (Euronext Brussels: ABLX) revealed top-line results from the recently…


Roche and Evotec terminate Ph II study with NR2B in treatment-resistant depression


German biotech firm Evotec AG (Xetra: EVT) and Swiss drug major Roche (SIX: ROG) say they have decided…


Pharma distribution in Central Europe in 2011: liberalization of non-pharmacy and on-line sales


Pharmaceutical distribution has been liberalized further in Central Europe in 2011, with Bulgaria making…

EuropeMarkets & MarketingPharmaceuticalRegulation

Roundup of upcoming cancer drug trials to be presented at ASCO


A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have…


FDA advisory panel backs continued use of Abbott’s Trilipix with statins


The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review…

Abbott LaboratoriesCardio-vascularNorth AmericaPharmaceuticalRegulationTrilipix

Record $3 billion disbursed in 2010 by Global Fund to Fight AIDS


The Global Fund to Fight AIDS, Tuberculosis and Malaria disbursed a record $3 billion in 2010. This helped…

Anti-viralsFinancialGlobalHealthcarePharmaceuticalTropical diseases

10% of US cancer patients abandoned oral drug therapy, often on cost grounds


In the USA, 10% of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs,…

HealthcareNorth AmericaOncologyPharmaceuticalPricing

Nycomed agrees to 9.6 billion euros takeover by Takeda


Despite just yesterday again saying that it "has not agreed to any such an agreement," this morning Takeda…

Mergers & AcquisitionsNycomedPharmaceuticalTakeda Pharmaceuticals

Global pharma market will see just 3%-6% growth over next five years, reaching $1,100 billion in 2015


Global spending for medicines will reach nearly $1,100 billion by 2015, reflecting a slowing compound…

GenericsGlobalMarkets & MarketingPatentsPharmaceutical

US cancer drug use and spending to rise sharply by 2013, followed by diabetes and CNS, says Medco


Expensive new cancer drugs treating increasing numbers of patients could drive cancer drug spending by…

DiabetesMarkets & MarketingNeurologicalNorth AmericaOncologyPharmaceuticalPricing

Astellas’ mirabegron improves key OAB symptoms in Ph III study


The US subsidiary of Japanese drug major Astellas (TSE: 4503) says that the results of a pivotal Phase…

Astellas PharmaGastro-intestinalsmirabegronPharmaceuticalResearch

Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market


US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator…

AriceptEisaiNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Amgen says Xgeva first drug to prevent spread of bone cancer in prostate cancer patients


Amgen (Nasdaq: AMGN), the world’s largest biotech company, has announced primary results of a pivotal…


Eisai gets Swiss approval for Halaven


Japanese drug major Eisai (TYO: 4532), says that its Halaven(eribulin) has been approved for use in…


Satisfaction with gastric cancer treatment options remains low, GfK study notes


In just over a month following the US Food and Drug Administration’s approval last fall of Swiss…

HerceptinMarkets & MarketingOncologyPharmaceuticalRoche

7066 to 7090 of 7233 results

Back to top